ArticleBioinformatics advances2026
TCRLens: structure-aware equivariant graph learning for TCR-pMHC-I recognition and immunogenic epitope discovery.
Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Accurate prediction of T-cell receptor (TCR) recognition of peptide-MHC class I (pMHC-I) complexes is a key challenge due to structural diversity and data sparsity. We introduce TCRLens, a structure-aware deep learning framework that models residue-level interactions across five critical interface zones using multi-scale graph representations and an equivariant graph neural network (EGNN). To mitigate data sparsity and severe class imbalance arising from limited negative samples, TCRLens incorporates a variational autoencoder-generative adversarial network (VAE-GAN) to generate structurally plausible weak-affinity interaction samples. We evaluated TCRlens across three prediction tasks including peptide-MHC binding, peptide-TCR recognition, and full-complex TCR-pMHC-I interaction and observed consistently strong performance. Results: Using curated dataset of human TCR-pMHC-I structural complexes from ATLAS and TCR3d, TCRLens outperforms state-of-the-art sequence-based, motif-based, and structure-aware methods, including NetMHCpan 4.2, CapsNet-MHC, RPEMHC, NetTCR-2.0, TITAN, PanPep, pMTnet, ERGO II, and STAG. Furthermore, TCRLens demonstrates robust cross-species generalization, achieving high predictive performance in swine and chicken MHC-I systems. These findings highlight the value of geometry-aware representation learning and generative data augmentation for capturing immunological specificity. TCRLens provides a unified and extensible platform for TCR-pMHC-I interaction modeling, with potential applications in epitope discovery and structure-guided vaccine design across both human and veterinary immunology. Availability and implementation: The code used in this study is publicly available at https://github.com/paopitsiri/TCRLens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.